Table 3.
NLR | Mortality at 1 mo | |||||
---|---|---|---|---|---|---|
Crude modela | Adjusted model Ib | Adjusted model IIc | ||||
OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
At admission | 1.08 (1.00, 1.17) | 0.058 | 1.08 (0.99, 1.17) | 0.087 | 1.00 (0.86, 1.16) | 0.971 |
Immediately after EVT | 1.05 (0.99, 1.11) | 0.111 | 1.04 (0.98, 1.10) | 0.219 | 1.05 (0.94, 1.17) | 0.422 |
Within 12–24 h after EVT | 1.14 (1.07, 1.20) | < 0.001 | 1.14 (1.07, 1.22) | < 0.001 | 1.18 (1.04, 1.33) | 0.008 |
Within 24–48 h after EVT | 1.13 (1.05, 1.22) | 0.002 | 1.12 (1.03, 1.21) | 0.005 | 1.16 (1.01, 1.35) | 0.044 |
Within 48–72 h after EVT | 1.22 (1.12, 1.33) | 0.001 | 1.23 (1.12, 1.35) | < 0.001 | 1.23 (1.03, 1.47) | 0.021 |
NLR Neutrophil-to-lymphocyte ratio, OR Odds ratio, CI Confidence interval, EVT Endovascular treatment
aCrude model: not adjusted for other covariates
bAdjusted model I: adjusted for sex and age
cAdjusted model II: sex; age; history of diabetes; history of chronic kidney disease; baseline NIHSS score; bridging intravenous thrombolysis; cardioembolic stroke; internal carotid artery occlusion; favorable collateral circulation; pneumonia during hospitalization; symptomatic intracerebral hemorrhage during hospitalization; sepsis during hospitalization; anticoagulation during hospitalization; use of invasive mechanical ventilation during hospitalization; use of vasopressors during hospitalization